Share This:
https://ntp.niehs.nih.gov/go/18922

TDMS Study 93020-05 Pathology Tables

NTP Experiment-Test: 93020-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 150-DAY                                      DIISOPROPYLCARBODIIMIDE                                  Date: 08/19/97
Route: SKIN APPLICATION                                                                                           Time: 14:04:40

                                                       150 DAY SUBCHRONIC




       Facility:  Microbiological Associates

       Chemical CAS #:  693-13-0

       Lock Date:  03/26/96

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 93020-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 150-DAY                                      DIISOPROPYLCARBODIIMIDE                                  Date: 08/19/97  
Route: SKIN APPLICATION                                                                                           Time: 14:04:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TG.AC HETEROZYGOUS TRANSGENIC MICE FEMALE 0            4.38         8.75         17.5         35           70              
                                                   MG/KG        MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 

  Animals Initially in Study                          10           10           10           10           10           10           
  Early Deaths                                                                                                                      
    Natural Death                                      1                                      1            2                        
    Moribund Sacrifice                                 1            2            2            1            2                        
  Survivors                                                                                                                         
    Terminal Sacrifice                                 8            8            8            8            6           10           

  Animals Examined Microscopically                    10            8           10            9            9           10           
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Small, Jejunum                           (9)          (2)          (2)          (1)          (2)          (10)         
      Carcinoma                                        1 (11%)                                                                      
   Liver                                              (10)         (6)          (7)          (7)          (6)          (10)         
      Leukemia Erythrocytic                            1 (10%)                                                                      
   Salivary Glands                                    (10)         (2)          (2)          (2)          (4)          (10)         
      Duct, Squamous Cell Carcinoma                                                                        1 (25%)                  
   Stomach, Forestomach                               (10)         (2)          (3)          (3)          (2)          (10)         
      Squamous Cell Papilloma                                                    2 (67%)      2 (67%)                   2 (20%)     
   Tooth                                              (3)          (4)          (4)          (6)          (3)          (7)          
      Odontoma                                         3 (100%)     2 (50%)      4 (100%)     6 (100%)     1 (33%)      6 (86%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (10)         (2)          (2)          (2)          (4)          (10)         
      Teratoma Benign                                                                                      2 (50%)                  
      Yolk Sac Carcinoma                                                         1 (50%)                                            
____________________________________________________________________________________________________________________________________

                                                             Page   2                                                               
NTP Experiment-Test: 93020-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 150-DAY                                      DIISOPROPYLCARBODIIMIDE                                  Date: 08/19/97  
Route: SKIN APPLICATION                                                                                           Time: 14:04:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TG.AC HETEROZYGOUS TRANSGENIC MICE FEMALE 0            4.38         8.75         17.5         35           70              
                                                   MG/KG        MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Spleen                                             (9)          (5)          (3)          (3)          (6)          (10)         
      Leukemia Erythrocytic                            1 (11%)                                                                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (10)         (3)          (4)          (4)          (4)          (10)         
      Squamous Cell Papilloma                                       1 (33%)                   1 (25%)                               
      Squamous Cell Papilloma, Multiple                1 (10%)                   1 (25%)                                            
      Dermis, Skin, Site of Application,                                                                                            
          Fibrosarcoma                                                           1 (25%)                                            
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma                                                                                                     1 (10%)     
      Skin, Site of Application, Squamous Cell                                                                                      
          Papilloma, Multiple                          1 (10%)                   1 (25%)      1 (25%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Nose                                               (10)         (5)          (1)          (2)          (4)          (10)         
      Respiratory Epithelium, Adenoma                  1 (10%)                                                                      
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             

                                                             Page   3                                                               
NTP Experiment-Test: 93020-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 150-DAY                                      DIISOPROPYLCARBODIIMIDE                                  Date: 08/19/97  
Route: SKIN APPLICATION                                                                                           Time: 14:04:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TG.AC HETEROZYGOUS TRANSGENIC MICE FEMALE 0            4.38         8.75         17.5         35           70              
                                                   MG/KG        MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   

   Multiple Organs                                   *(10)        *(8)         *(10)        *(9)         *(9)         *(10)         
      Leukemia Erythrocytic                            1 (10%)                                                                      
____________________________________________________________________________________________________________________________________

                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 

                                                             Page   4                                                               
NTP Experiment-Test: 93020-05               INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (a)                     Report: PEIRPT02
Study Type: 150-DAY                                      DIISOPROPYLCARBODIIMIDE                                  Date: 08/19/97  
Route: SKIN APPLICATION                                                                                           Time: 14:04:40  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         TG.AC HETEROZYGOUS TRANSGENIC MICE FEMALE 0            4.38         8.75         17.5         35           70              
                                                   MG/KG        MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)             6           3           6           7           3           8               
     Total Primary Neoplasms                            8           3          10          10           4           9               
                                                                                                                                    
   Total Animals with Benign Neoplasms                  5           3           6           7           3           8               
     Total Benign Neoplasms                             6           3           8          10           3           9               
                                                                                                                                    
   Total Animals with Malignant Neoplasms               2                       2                       1                           
     Total Malignant Neoplasms                          2                       2                       1                           
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    

____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              

                                                             Page   5                                                               
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------